Life Insurance Awareness Month Social Media Campaign
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Why Life Insurance Matters
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Family Fact Friday
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Whole Life Insurance Basics
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Life Insurance for Families
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
The Cost of Waiting
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
The History of Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Group Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Variable Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Life Insurance for Young Professionals
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Universal Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Business Owner and Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Life Insurance for High-Net-Worth Individuals
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Life Insurance for Retirees
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Getting Creative with a Life Insurance Awareness Month Campaign
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
The Pros and Cons of Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Singles and Life Insurance
Part of a social media campaign that I created through Canva on my Linkedin profile to reach audiences in need of life insurance or other financial products.
Social Media Campaign for Global Financial Impact
In September 2024, I created a series of consistent social media posts to promote Life Insurance Awareness Month and spread awareness.
The future of cancer is now.
Six CAR-T cell therapies are now approved in the US, and cell therapy’s impact on cancer care is growing at a rapid pace. One of the next goals in cell therapy is to improve efficiency by reprograming patients’ cells in vivo – that is, inside their own bodies. How do you think the evolution of CAR-T cell therapy is impacting lives and medicine as we know it? “The promise of changing the ability of a cell to alter the course of disease with a simple injection is very exciting and helped tremendously by efforts and success of the Covid-19 mRNA vaccines.”
#celltherapies #CARtcelltherapy #mRNA #bioscience
#celltherapies #CARtcelltherapy #mRNA #bioscience
HIV vaccine being developed by Johnson & Johnson and the U.S. National Institute of Health fails clinical trial
An experimental HIV vaccine being developed by Johnson & Johnson and the U.S. National Institute of Health wasn’t effective at preventing infection in a large study, independent trial monitors determined after reviewing initial results. The trial will be discontinued as a result. What do you think will be the next step for researchers in preventing infection?
“We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV.” - Penny Heaton, M.D., Global Therapeutic Area Head for Vaccines at Janssen
#HIVvaccine #HIV #HIVprevention #clinicaltrial
https://lnkd.in/eWmhYZ2y
“We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV.” - Penny Heaton, M.D., Global Therapeutic Area Head for Vaccines at Janssen
#HIVvaccine #HIV #HIVprevention #clinicaltrial
https://lnkd.in/eWmhYZ2y
The rollout and readout of Alzheimer drugs is one of the biggest biotech trends that is shaping 2023.
The accelerated approval of lecanemab, branded as Leqembi, signaled a hopeful development for the treatment of Alzheimer’s disease. What else do you think is on the horizon for Alzheimer’s disease treatment?
“Beta amyloid directed antibodies have become one of the most controversial drug classes in recent history,” said Fady Riad, CEO of the consulting firm Centurion Life Sciences. “The approval of Aduhelm in 2021 led to significant scrutiny with regards to the efficacy and safety profiles of this drug and its entire class.”
#Alzheimersdisease #biotech #Alzheimers hashtag#Alzheimerstreatment
https://lnkd.in/evUdeFEs
“Beta amyloid directed antibodies have become one of the most controversial drug classes in recent history,” said Fady Riad, CEO of the consulting firm Centurion Life Sciences. “The approval of Aduhelm in 2021 led to significant scrutiny with regards to the efficacy and safety profiles of this drug and its entire class.”
#Alzheimersdisease #biotech #Alzheimers hashtag#Alzheimerstreatment
https://lnkd.in/evUdeFEs
Awakn Initiates Investigative Study Of Novel Formulation Of (S)-Ketamine to assess dissociative effect.
The thoughtful team Awakn Life Sciences initiated an investigative study of a novel formulation of (S) – Ketamine to assess dissociative effect. Awakn is a biotechnology company focused on developing therapeutics to treat addiction. With a near-term focus on Alcohol Use Disorder (AUD), the study’s participants will consist of harmful drinkers. If the results of this study are positive, it will potentially lead to a global licensing agreement of their patent pending oral thin film (S) – Ketamine formulation.
Anthony Tennyson, Awakn CEO said, “This is an exciting development for Awakn which we believe will strengthen our innovative pipeline of therapeutics. Critically, it also has the potential to improve treatment options and experiences for so many people suffering from Alcohol Use Disorder, with so few effective options available to them, there has never been a greater need.”
#AlcoholUseDisorder #therapeutics #Phase1 #Ketamine
https://lnkd.in/eUeQagei
Anthony Tennyson, Awakn CEO said, “This is an exciting development for Awakn which we believe will strengthen our innovative pipeline of therapeutics. Critically, it also has the potential to improve treatment options and experiences for so many people suffering from Alcohol Use Disorder, with so few effective options available to them, there has never been a greater need.”
#AlcoholUseDisorder #therapeutics #Phase1 #Ketamine
https://lnkd.in/eUeQagei
Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial
The devoted team Sparrow Pharmaceuticals, Inc., dedicated to developing innovative therapies to address unmet needs in both endocrinology and rheumatology, are excited to share some great news. The first patient has been dosed in the phase 2 clinical trial, for the treatment of ACTC-dependent Cushing’s syndrome.
“Dosing our first patient in this phase 2 trial is an important milestone in our clinical development process of SPI-62. Cushing is a devastating rare disease with debilitating morbidities such as depression, bone loss, and diabetes, and if left untreated, high levels of mortality. Current treatments have limited efficacy or serious side effects, so there is a pressing need for new treatments that help these patients mitigate the effects of hypercortisolism.” -Frank Czerwiec, MD, PhD, Chief Medical Officer of Sparrow
#biopharma #cushingssdynrome #clinicaltrial #depression #diabetes #hypercortisolism
“Dosing our first patient in this phase 2 trial is an important milestone in our clinical development process of SPI-62. Cushing is a devastating rare disease with debilitating morbidities such as depression, bone loss, and diabetes, and if left untreated, high levels of mortality. Current treatments have limited efficacy or serious side effects, so there is a pressing need for new treatments that help these patients mitigate the effects of hypercortisolism.” -Frank Czerwiec, MD, PhD, Chief Medical Officer of Sparrow
#biopharma #cushingssdynrome #clinicaltrial #depression #diabetes #hypercortisolism
Load More